ANI Pharmaceuticals Inc (NASDAQ: ANIP) is a specialty pharmaceuticals company that develops, manufactures, and markets branded and generic prescription pharmaceutical products. Revenue comes from product sales across its branded, generic, and contract development and manufacturing segments. The 10-K filed 2026-02-27 (accession 0001023024-26-000014) covers the fiscal year ended December 31, 2025, but the filing excerpts provided do not contain sufficient detail to state segment revenue splits, specific product names, customer concentration, geographic mix, headcount, founding year, CEO tenure, or competitive positioning with supporting numbers. Accordingly, those specifics are omitted here. What the filing confirms is that ANIP is incorporated in a U.S. state, trades on a national exchange under the ticker ANIP with common stock at $0.0001 par value, and files as a well-known seasoned issuer under the Securities Exchange Act of 1934.

Source: SEC 10-K, filed 2026-02-27

Industry: Pharmaceutical Preparations Peers: Atea Pharmaceuticals Inc BIODELIVERY SCIENCES INTERNATIONAL INC Collegium Pharmaceutical Inc Edgewise Therapeutics Inc Nektar Therapeutics Johnson & Johnson Phibro Animal Health Corp Tricida, Inc.